The ARCHITECT and Alinity urine NGAL assays, urine NephroCheck test, and urine and plasma BioPorto NGAL tests to help assess the risk of acute kidney injury

The ARCHITECT and Alinity urine NGAL assays, urine NephroCheck test, and urine and plasma BioPorto NGAL tests to help assess the risk of acute kidney injury for people who are being considered for admission to critical care (Diagnostic Assessment Review) 

As part of the NICE Diagnostic Assessment Review (DAR) process, the Aberdeen external assessment group (EAG) were commissioned to conduct a systematic review of diagnostic accuracy evidence and develop a decision analytic model to determine the cost-effectiveness of the candidate tests.  This assessment is ongoing and can be followed at: Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test). In development [GID-DG10028].

HERU researchers involved in this research project: Elisabet Jacobsen, Dwayne Boyers and Graham Scotland

External collaborators: Brazzelli, M., Cummins, E. and Campbell, M. (Health Services Research Unit (HSRU), University of Aberdeen).